gsk_boronia_australia

GSK to axe 650 positions across US workforce

pharmafile | September 6, 2018 | News story | Manufacturing and Production GSK, GlaxoSmithKline, pharma 

GlaxoSmithKline has announced its intention to cut 650 employees from its current US workforce, with the cutbacks coming as part of a global restructuring effort announced in July earlier this year.

The cutbacks are divided across a number of areas: 100 positions will be terminated in North Carolina, while 450 will be culled from the company’s sales force across all 50 states. One hundred more positions will also be eliminated at GSK’s Philadelphia office.

“The downsizing is intended to contribute to a major cost savings and improve the operational performance within certain sections of our Commercial and Commercial support operations,” GSK said in a letter to the NC Department of Commerce.

GSK employs around 15,000 in total in the US. All affected employees have been notified, and are expected to have vacated their roles by November this year.

The firm had a said that the restructuring effort would “significantly improve the competitiveness and efficiency of [its] cost base with savings delivered primarily through supply chain optimisation and reductions in administrative costs”. This commitment was reiterated in the company’s release: “The savings from this restructuring will be fully reinvested in R&D and to support commercialisation of new products, which will fuel innovation and our future growth,” the company said.

Matt Fellows

Related Content

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase …

Latest content